Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

BACKGROUND: Currently, several biologic agents are available for the treatment of moderate-to-severe plaque psoriasis, including newer agents with similar mechanisms of action and efficacy; therefore, there is a need to evaluate their efficiency in terms of cost effectiveness. OBJECTIVE: This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Erin, Nuñez, Mercedes, Svedbom, Axel, Dilla, Tatiana, Hartz, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237133/
https://www.ncbi.nlm.nih.gov/pubmed/30519064
http://dx.doi.org/10.2147/CEOR.S167727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237133/
https://www.ncbi.nlm.nih.gov/pubmed/30519064
http://dx.doi.org/10.2147/CEOR.S167727

Ejemplares similares